AZ's Imfinzi approved in early lung cancer in China

The Chinese regulator has approved AstraZeneca’s Imfinzi in an early form of lung cancer after treatment with chemotherapy and radiation.

DeepMatter will help AstraZeneca digitise discovery chemistr...

Scotland backs AZ’s Lynparza for first-line ovarian cancer m...

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

NICE backs Lynparza across the board for BRCA+ovarian cancer

FDA grants AZ's Imfinzi fast review in new lung cancer use

The FDA has granted AstraZeneca’s Imfinzi immunotherapy a faster six-month review in patients with extensive-stage small cell lung cancer.